Vanguard Group Inc. Has $284.42 Million Stock Holdings in Privia Health Group, Inc. $PRVA

Vanguard Group Inc. cut its holdings in Privia Health Group, Inc. (NASDAQ:PRVA) by 0.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 11,995,970 shares of the company’s stock after selling 102,963 shares during the quarter. Vanguard Group Inc. owned about 0.10% of Privia Health Group worth $284,424,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PRVA. Royal Bank of Canada grew its position in shares of Privia Health Group by 63.5% in the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock valued at $5,514,000 after purchasing an additional 95,371 shares during the period. AQR Capital Management LLC grew its position in shares of Privia Health Group by 24.7% in the 1st quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock valued at $916,000 after purchasing an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Privia Health Group by 3.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock valued at $2,666,000 after purchasing an additional 3,714 shares during the period. Intech Investment Management LLC grew its position in shares of Privia Health Group by 55.1% in the 1st quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock valued at $1,270,000 after purchasing an additional 20,082 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in shares of Privia Health Group in the 1st quarter valued at approximately $154,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Privia Health Group

In related news, CEO Parth Mehrotra sold 26,509 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $22.11, for a total value of $586,113.99. Following the sale, the chief executive officer owned 555,443 shares in the company, valued at approximately $12,280,844.73. This represents a 4.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew Shawn Morris sold 1,017 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $24.96, for a total value of $25,384.32. Following the completion of the sale, the director owned 68,188 shares in the company, valued at approximately $1,701,972.48. This trade represents a 1.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 274,255 shares of company stock worth $6,299,092. Company insiders own 5.70% of the company’s stock.

Privia Health Group News Roundup

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia Health reported first-quarter results that beat revenue expectations, with sales of $603.85 million versus the $560.99 million estimate, and EPS of $0.19 versus $0.08 expected. The company also said revenue rose 25.8% year over year, and it reiterated full-year 2026 guidance. Article Title
• Positive Sentiment: The company’s updated 2026 outlook calls for revenue of $2.4 billion to $2.5 billion, which is in line with or slightly above market expectations and supports the case for continued growth. Article Title
• Neutral Sentiment: Investors are also parsing the Q1 2026 earnings call transcript and related earnings coverage for management commentary on margins, utilization trends, and the path to hitting full-year targets. Article Title
• Negative Sentiment: Two insider-selling reports may be weighing on sentiment: the CFO sold about $179,690 of stock and a director sold about $427,229 of stock, which can signal caution even when fundamentals are improving. Article Title Article Title

Privia Health Group Stock Performance

NASDAQ PRVA opened at $23.10 on Friday. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $26.51. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of 144.35, a PEG ratio of 1.50 and a beta of 0.96. The stock’s 50 day moving average price is $22.73 and its two-hundred day moving average price is $23.34.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.11. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The company had revenue of $603.85 million for the quarter, compared to analysts’ expectations of $560.99 million. During the same quarter in the prior year, the business posted $0.22 EPS. The business’s revenue was up 25.8% compared to the same quarter last year. On average, equities research analysts forecast that Privia Health Group, Inc. will post 0.37 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $36.00 price objective on shares of Privia Health Group in a research report on Thursday, February 26th. Canaccord Genuity Group cut their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research note on Friday, March 27th. Citigroup cut their target price on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Finally, Evercore set a $26.00 target price on Privia Health Group in a research note on Wednesday, April 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $31.23.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.